Merck & Company Inc's Fiscal Year is From January To December - All Figures are in USD, Billions.
The item "Begin-Period-Cashflow" stands at 44.81 Billion United States Dollars for the trailing twelve months (TTM) period ending 09/30/2025.
Merck & Company Inc's third quarter result of 8.07 Billion USD for the item "Begin Period Cashflow" represents a decrease of -7.55 percent compared to it's second quarter result.
Also, Merck & Company Inc's third quarter result of 8.07 Billion USD for the item "Begin Period Cashflow" represents a decrease of -29.02 percent compared to it's third quarter result of last year.
Looking again at the trailing twelve months series (TTM), Merck & Company Inc's third quarter result of 44.81 Billion USD for the item "Begin Period Cashflow" represents a decrease of -6.86 percent compared to it's second quarter result.
Regarding the One-Year-Change of the series, the current value constitutes an increase of 37.47 percent compared to the value the year prior.
The 1 year change in percent is 37.47.
The 3 year change in percent is 22.50.
The 5 year change in percent is 23.07.
The 10 year change in percent is 32.92.
| Logo | Name | Market Cap (USD) |
|---|---|---|
![]() | Eli Lilly and Company - Begin Period Cashflow | 905,699,262,464.00 |
![]() | Johnson & Johnson - Begin Period Cashflow | 486,508,953,600.00 |
![]() | AbbVie Inc - Begin Period Cashflow | 399,570,305,024.00 |
![]() | Roche Holding AG - Begin Period Cashflow | 317,433,206,677.55 |
![]() | AstraZeneca PLC - Begin Period Cashflow | 280,205,508,085.11 |